About this test
Quantifies ERBB2 (HER2) mRNA expression in tumour tissue by RT-qPCR. It is a supplementary result: treatment decisions rely on validated immunohistochemistry (IHC) and in situ hybridisation (ISH), which this test does not replace.
Breast and gastric cancer, supplementary marker
Quantifies ERBB2 (HER2) mRNA expression in tumour tissue by RT-qPCR. It is a supplementary result: treatment decisions rely on validated immunohistochemistry (IHC) and in situ hybridisation (ISH), which this test does not replace.
As an additional data point alongside IHC/ISH when the clinician or pathologist requests it.
Offered on request. Current guidelines give this test a limited role in routine practice; results are reported as genotype or expression data for the ordering clinician to interpret.
Results are reported to the ordering physician and should be interpreted in clinical context.
Contract pricing and turnaround times are provided on request for laboratories and clinics.